Test utilization—are you driving the bus, chased by the bus or under it?

Debbi Tiffany MSED, MLS(ASCP)CM SCCM SLSCM
Director of Laboratory Services
SwedishAmerican Health System
Rockford, Illinois
Official disclaimer and introduction

- Who am I and why am I presenting this topic?
We all know it’s out there

The Future of Lab Utilization Management--Are Lab Formularies the Answer?

Utilization Management 2013

Optimal Utilization of Laboratory Testing

Managing physician use of laboratory tests.

“Choosing Wisely” Program Wants to Encourage Better Utilization of Clinical Pathology Laboratory Tests

Pulling back the reins on superfluous testing

Laboratory Utilization Improvements: Approaches, Outcomes and Impact

An administrative intervention to improve the utilization of laboratory tests within a university hospital

How labs are taming test utilization
Test Utilization
Where do I start?

“It is the direction and not the magnitude which is to be taken into consideration.”

Thomas Paine

Source: http://9teen87spostcards.blogspot.com/
High level view

• What is my menu?
• Where are these tests being done?
• What instrument platforms do I have?
• Who is ordering them?
• How much are they costing me?
• Can we do anything better?
  – TAT
  – Pricing
  – Workflow
Tracking what you do

• Year to year comparisons
  – Top 25 in house and referred tests
  – Look for change in volume or order pattern change
    • Physician or practice changes
    • Effect of CPOE, LIS, or HIS changes
    • Evidence based medicine or practice guideline changes and updates
    • Viability of keeping a test in-house
Lipoprotein (a)

<table>
<thead>
<tr>
<th>Series1</th>
<th>FY08</th>
<th>FY09</th>
<th>FY10</th>
<th>FY11</th>
<th>FY12</th>
<th>FY13</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>538</td>
<td>484</td>
<td>315</td>
<td>152</td>
<td>147</td>
<td>53</td>
</tr>
</tbody>
</table>
REVIEWING SEND OUT TESTS
Reviewing your send out tests—things you can do yourself

• Year to year comparisons
  – Top 25 referred tests
  – Look for change in volume or order pattern change
    • Physician or practice changes
    • Effect of CPOE, LIS, or HIS changes
    • Evidence based medicine or practice guideline changes and updates
  – Can I do any of these tests myself?
# Hepatitis B Core Ab, Total

<table>
<thead>
<tr>
<th>FY12 volume</th>
<th>send out cost</th>
<th>in house cost</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>$9.92</td>
<td>$3.30</td>
</tr>
<tr>
<td>total cost</td>
<td>$3,948.16</td>
<td>$1,313.40</td>
</tr>
<tr>
<td>Savings</td>
<td></td>
<td>$2,634.76</td>
</tr>
</tbody>
</table>
# 25-OH Vitamin D

<table>
<thead>
<tr>
<th></th>
<th>send out cost</th>
<th>in house cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY11 volume</td>
<td>$16.25</td>
<td>$8.95</td>
</tr>
<tr>
<td>total cost</td>
<td>$213,671.25</td>
<td>$117,683.55</td>
</tr>
<tr>
<td>savings</td>
<td></td>
<td>$95,987.70</td>
</tr>
</tbody>
</table>
Evidence based medicine or practice guidelines

• The “trend” of celiac testing
• Following guidelines

‘Go ahead honey, it’s gluten free!’
Celiac serology—who, what, where, and can I do better?

• Celiac testing being ordered by family practice, internal medicine, and mid-level providers like PA’s and APN’s and not just gastroenterologists

• Analysis of testing provided by a specialized laboratory (Laboratory “P”) indicated a battery of tests being used for celiac serology testing

• Other national reference laboratories were using reflex testing in response to published guidelines
## Celiac serology—shotgun versus reflex

<table>
<thead>
<tr>
<th></th>
<th>Lab P</th>
<th>Lab A</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY12 volume</td>
<td>182</td>
<td>182</td>
</tr>
<tr>
<td>total cost</td>
<td>$42,220.36</td>
<td>$6,035.12</td>
</tr>
<tr>
<td>savings</td>
<td>$36,185.24</td>
<td>$36,185.24</td>
</tr>
</tbody>
</table>
Reviewing send out tests—now you need some expert help

• How do I compare to other labs?
  – Do we order more/less/same?

• Are we ordering
  – Inappropriate tests?
  – Outdated tests?
  – Duplicate or tests with limited use?
What to look at and why?

- Mis-utilization/underutilization
  - APC resistance and Factor V Leiden
- Suboptimal/overutilization
  - Ova and Parasite testing
- Outdated or inappropriate testing
  - H. pylori serology testing
  - Aldolase
APC and Factor V Leiden

• “For factor V Leiden testing, functional testing (i.e. activated protein C (APC) resistance) is clinically equivalent to DNA testing as an initial test and is less costly.”

• “Abnormal APC resistance test results can be followed up with PCR testing for confirmation and to distinguish homozygotes from heterozygotes.”

Screen with APC
Where are we now?

- Still too many Factor V Leiden being sent out
  - Inpatients
  - “shotgun orders” by certain providers
    - One oncologist
    - Multiple locum tenens hospitalists

- What now?
  - CPOE order screen/order set redesign
  - Pathologist intervention with certain providers
  - Bring the test in-house to better scrutinize orders?
Ova & parasite testing

• First referred out in FY09
  – Staffing
  – Expertise

• No criteria for specimen submission or pre-screening
  – “If you have a specimen, it gets sent out”
Based on consultation……

- Specimen criteria set up for sending out O&P beginning June 2011 and communicated by pathologist responsible for Microbiology
  - If patient is immunocompromised
  - If patient has a travel history
- If criteria not met, in-house Giardia and Cryptosporidium testing performed and specimen held 30 days
  - This information is communicated in report
- In 1st year
  - 57% reduction in unnecessary testing
  - Approximately $38,000 in savings
<table>
<thead>
<tr>
<th></th>
<th>FY09</th>
<th>FY10</th>
<th>FY11</th>
<th>FY12</th>
<th>FY13</th>
<th>FY14 proj</th>
</tr>
</thead>
<tbody>
<tr>
<td>Series1</td>
<td>720</td>
<td>621</td>
<td>1117</td>
<td>480</td>
<td>472</td>
<td>312</td>
</tr>
</tbody>
</table>

We have a problem
Outdated or inappropriate testing

- *H. pylori* serology testing is not recommended per evidence based medicine
- Better methods available
  - Breath test
  - Stool antigen
- SAH appeared to order more than “normal” compared to other labs
The graph shows the levels of H. pylori IgM from FY08 to FY12. The highest level was in FY11, with a value of 406. The lowest was in FY08, with a value of 28. The levels in FY09 and FY10 were 38 and 61, respectively. In FY12, the level was 378.
• Drill down revealed inappropriate ordering across the system and not isolated to any one clinic or provider

• Communication regarding more appropriate testing (newsletter, specific individual letters, electronic “Dr. Hub” posting) not effective at changing ordering behavior

• All *H. pylori* serology tests removed from computerized order entry system and letters issued announcing discontinuation as of June 2012
  – Link to appropriate testing guidelines provided in letters
Aldolase

- Considered outdated and of little clinical utility
- Drill down on orders
  - Single location
  - PA’s and APN’s
- Tried communication strategy regarding use of CK as an alternative
FUTILITY

No matter how hard you try, you will fail.
## Aldolase—my nemesis

<table>
<thead>
<tr>
<th></th>
<th>FY08</th>
<th>FY09</th>
<th>FY10</th>
<th>FY11</th>
<th>FY12</th>
<th>FY13</th>
</tr>
</thead>
<tbody>
<tr>
<td>Series1</td>
<td>154</td>
<td>165</td>
<td>150</td>
<td>159</td>
<td>190</td>
<td>17</td>
</tr>
</tbody>
</table>

Still incomplete intervention
Success factors

• Data, data, and more data
• Willingness to dig into data
  - Get it to “talk to me”
• Real world savings
• Support from our reference lab (on-call pathologist, subject experts, online resources)
• “Can-do” attitude from lab supervisors to bring testing in-house if needed
• Properly motivated and informed physicians
Strive for progress not for perfection.

Thank You!